YHC1144

YHC1144 is a preclinical-stage small molecule drug candidate being developed through a collaboration between Yuhan Corporation and ABL Bio. It is specifically designed for the treatment of neurodegenerative brain diseases. The program leverages Yuhan's expertise in small molecule drug discovery and ABL Bio's research into central nervous system (CNS) biology. While the specific molecular target of YHC1144 has not been publicly disclosed in pipeline summaries, the candidate is part of a broader effort by Yuhan to expand its CNS portfolio, which includes programs targeting protein aggregation and lysosomal dysfunction. YHC1144 is currently undergoing early-stage development to address underlying pathological mechanisms in conditions such as Parkinson's or Alzheimer's disease.